Is SMMT a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Ivonescimab FDA review and first approval, with product revenue (ttm) at ~$0 (pre-commercial). The bear case rests on summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. Analysts covering it are spread from $9.82 to $40.94, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $9.82, -22.4% from the $12.66 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Ivonescimab FDA review and first approval. The FDA has accepted Summit's BLA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after TKI therapy, with a target decision date of November 14, 2026. The most optimistic analyst target on SMMT is $40.94, +223.4% from the $12.66 price. That figure is only reachable if this thesis works close to its best case.

Summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value. The competitive field is intensifying, with Pfizer/3SBio and Bristol Myers Squibb/BioNTech (pumitamig) also developing PD-1/PD-L1 by VEGF bispecifics, and Merck's Keytruda is the entrenched standard of care. The company depends on its license from Akeso and on manufacturing and clinical execution across many regions. With ongoing cash burn and no product sales, Summit may need to raise capital, diluting shareholders, and its stock is highly volatile and prone to large single-day moves around catalysts. The most pessimistic published target is $9.82, -22.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Summit Therapeutics is a clinical-stage biopharmaceutical company focused almost entirely on ivonescimab, a first-in-class tetravalent bispecific antibody that targets both PD-1 an

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Ivonescimab FDA review and first approval) stalling in the reported numbers rather than in the narrative, the risk above (summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, a bispecific antibody that blocks both PD-1 and VEGF. Its main focus is treating non-small cell lung cancer, with additional programs in colorectal and other cancers. It does not yet sell an approved product.

Ivonescimab is a first-in-class tetravalent bispecific antibody that targets PD-1 and VEGF at the same time. Summit licensed it from China-based Akeso in 2023 and is developing it for lung and other cancers. In trials it has extended progression-free survival versus Merck's Keytruda in some NSCLC settings.

No. Summit is a pre-revenue clinical-stage biotech with no meaningful product sales, so it runs net losses and burns cash funding its trials. It reported about $122.3 million of operating cash use in the first quarter of 2026. Profitability would depend on approving and commercializing ivonescimab.